DOI: http://dx.doi.org/10.18203/2349-3933.ijam20220792

A rare cause of anaemia in multiple myeloma

Lakshmipriya Kalidindi, Mahendra Kumar Kalapan, Arunkumar Bathena, Jagadeesan Mohanan

Abstract


 Multiple myeloma is a neoplastic plasma cell dyscrasia. Anaemia in multiple myeloma is usually related to many factors, of which the commonest cause being anaemia of chronic disease. We reported a 67 years old hypertensive male presented with low back pain and loss of appetite. Investigations revealed severe anaemia and elevated total serum protein with albumin/globulin (A/G) reversal (1:4). Bone marrow aspiration revealed plasma cell dyscrasia. Skeletal survey evaluation showed multiple osteolytic lesions. Serum protein electrophoresis revealed M spike in gamma globulin region with immunofixation suggestive of IgG and kappa monoclonal gammopathy. He was diagnosed as a case of multiple myeloma.. On evaluating the cause of severe anaemia, interestingly various findings suggestive of Autoimmune hemolytic anaemia (AIHA) were found. Packed red blood cell transfusion along with steroids was done for correction of severe anaemia. Review of literature showed that only about 4% of AIHA patients had multiple myeloma. We reported a rare case of multiple myeloma who presented with AIHA.


Keywords


Multiple myeloma, Anaemia, Autoimmune, AIHA

Full Text:

PDF

References


Pirofsky B. Clinical aspects of autoimmune hemolytic anaemia. Semin Hematol. 1976;13(4):251-65.

Zucchelli P, Pasquali S. Multiple myeloma and plasma cell dyscrasias. Suki and Massry’s therapy of renal diseases and related disorders. Boston: Springer; 1998: 529-539.

Shah BK, Uprety D, Tretheway D. Multiple myeloma presenting with autoimmune hemolytic anaemia. Indian J Hematol Blood Transfus. 2014;30(1):38-9.

Dispenzieri A, Kyle RA. Multiple myeloma: clinical features and indications for therapy. Best Pract Res Clin Haematol. 2005;18(4):553-68.

Fosså A, Brandhorst D, Myklebust JH, Seeber S, Nowrousian MR. Relation between S-phase fraction of myeloma cells and anaemia in patients with multiple myeloma. Exp Hematol. 1999;27(11):1621-6.

Musto P, Falcone A, D'Arena G, Scalzulli PR, Matera R, Minervini MM, et al. Clinical results of recombinant erythropoietin in transfusion-dependent patients with refractory multiple myeloma: role of cytokines and monitoring of erythropoiesis. Eur J Haematol. 1997;58(5):314-9.

Silvestris F, Cafforio P, Tucci M, Dammacco F. Negative regulation of erythroblast maturation by Fas-L(+)/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anaemia in multiple myeloma. Blood. 2002;99(4):1305-13.

Yi Y, Zhang GS, Gong FJ, Yang JJ. Multiple myeloma complicated by Evans syndrome. Intern Med J. 2009;39(6):421-2.

Pasquale R, Giannotta JA, Barcellini W, Fattizzo B. Bortezomib in autoimmune hemolytic anaemia and beyond. Ther Adv Hematol. 2021;12:20406207211046428.

Hamdan DO, Truhlar BS, Earl H, Rudolph DO. Multiple Myeloma Presenting as Autoimmune Hemolytic Anaemia: Bortezomib as Potential Therapy for Autoimmune Hemolytic Anaemia Refractory to Standard Corticosteroid Therapy. Clin Rev Cases. 2019;2(2):1-4.

Wada H, Yata K, Mikami M, Suemori S, Nakanishi H, Kondo T, et al. Multiple myeloma complicated by autoimmune hemolytic anaemia. Intern Med. 2004;43(7):595-8.

Ting WC, Cavill I, Jacobs A, Kaaba S, May A, Smith S, et al. Anaemia in patients with myelomatosis. Br J Cancer. 1982;45(6):887-94.

Friedland M, Schaefer P. Myelomatosis and hemolytic anaemia. Hemolytic anaemia, a rare complication of multiple myeloma, is successfully managed by splenectomy. R I Med J. 1979;62(12):469-71.